- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01827644
Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers
November 8, 2017 updated by: GlaxoSmithKline
A Single Center, Randomized, Open-Label, Sequential, Single Dose, 4-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Two Prototype Formulations of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers
This will be a randomized, open-label, sequential, single dose, 4-period crossover study.
This study is being conducted to measure the relative bioavailability of the original gelatin capsule (GC) formulation and two new formulations (hydroxypropyl-methylcellulose [HPMC] capsule and enteric coated tablet [ECT]) of afuresertib (AFU), in the fed and fasted state.
The study will be composed of Screening, Treatment, and Follow-up Periods.
Screening assessments to determine subject eligibility will be performed within 3 weeks prior to the first dose of study drug in the Treatment Period.
Eligible subjects will be randomized to receive 4 of the 6 possible study treatments (A: AFU GC administered in a fasted state, B: AFU GC administered in a fed state, C: AFU HPMC capsule administered in a fasted state, D: AFU HPMC capsule administered in a fed state, E: AFU ECT administered in a fasted state, F: AFU ECT administered in a fed state) in 4 treatment periods (one per treatment period).
Subjects will receive a single dose of one of the six study treatments (A, B, C, D, E, F) on Day 1 of each Dosing Period, according to one of the 6 treatment sequences (CEDA, EFAB, ABFC, BDCE, FCBD, DAEF).
There will be a minimum of 10 Day washout period between the doses administered in each Treatment Period.
A Follow-up visit will be conducted within 10-14 days after the last dose.
A subject's total time involved in the study will be approximately 9 weeks.
At least 36 subjects will be enrolled in the study, to ensure that at least 6 subjects will be randomized to receive each treatment sequence.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- Male or female between 18 and 40 years of age inclusive, at the time of signing the informed consent
- Body weight >=50 kilograms (kg) and body mass index (BMI) <=32 kg/m^2 (square meter)
- A female subject is eligible to participate if she is of: (A) Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy or postmenopausal defined as 12 months of spontaneous amenorrhea (B) Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotropin (hCG) test at Screening and prior to dosing, AND: agrees to use one of the acceptable contraception methods
- Male subjects with female partners of child-bearing potential must agree to use one of the acceptable contraception methods.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5 x Upper Limit of Normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Based on single or averaged corrected QT interval (QTc) values of triplicate electrocardiograms (ECGs) obtained over a brief recording period: QTc <450 milliseconds (msec) or QTc <480 msec in subjects with Bundle Branch Block
Exclusion Criteria:
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- History of gastroesophageal reflux disease (GERD), dyspepsia, gastrointestinal (GI) bleeding, GI surgery that could affect motility
- History of atrial arrhythmias
- History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- History of sensitivity to heparin or heparin-induced thrombocytopenia
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation
- Use of prescription or non-prescription medications, vitamins, and dietary or herbal supplements (including St John's Wort) within 7 days (or 14 days if the drug/supplement is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study drug until completion of the Follow-up Period, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study
- Unable to abstain from smoking tobacco or the use of nicotine-containing products while admitted to the clinic
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of Study Drug on Day 1 of Dosing Period 1, until completion of the Follow-up Period
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of Screening
- History of heavy use of tobacco- or nicotine-containing products within 6 months prior to Screening.
- A positive drug/alcohol screen at Screening or upon check-in to the clinic on Day -1 of each Dosing Period
- A positive test for Human Immunodeficiency Virus (HIV) antibody
- Pregnant females as determined by positive serum hCG test at Screening or prior to dosing.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
- Lactating females
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sequence 1
Subjects will receive single doses of AFU HPMC capsule administered in a fasted state, AFU ECT administered in a fasted state, AFU HPMC capsule administered in a fed state and AFU GC administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
|
White opaque hard gelatin capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib GC administered in fasted state
White opaque HPMC capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
White to off white, round, biconvex coated tablet containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib ECT administered in fasted state
White opaque HPMC capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
|
EXPERIMENTAL: Sequence 2
Subjects will receive single doses of AFU ECT administered in a fasted state, AFU ECT administered in a fed state, AFU GC administered in a fasted state and AFU GC administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
|
White opaque hard gelatin capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib GC administered in fasted state
White to off white, round, biconvex coated tablet containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib ECT administered in fasted state
White opaque hard gelatin capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib GC administered in fed state
White to off white, round, biconvex coated tablet containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib ECT administered in fed state
|
EXPERIMENTAL: Sequence 3
Subjects will receive single doses of AFU GC administered in a fasted state, AFU GC administered in a fed state, AFU ECT administered in a fed state and AFU HPMC capsule administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
|
White opaque hard gelatin capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib GC administered in fasted state
White opaque HPMC capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
White opaque hard gelatin capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib GC administered in fed state
White to off white, round, biconvex coated tablet containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib ECT administered in fed state
|
EXPERIMENTAL: Sequence 4
Subjects will receive single doses of AFU GC administered in a fed state, AFU HPMC capsule administered in a fed state, AFU HPMC capsule administered in a fasted state and AFU ECT administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
|
White opaque HPMC capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
White to off white, round, biconvex coated tablet containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib ECT administered in fasted state
White opaque HPMC capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
White opaque hard gelatin capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib GC administered in fed state
|
EXPERIMENTAL: Sequence 5
Subjects will receive single doses of AFU ECT administered in a fed state, AFU HPMC capsule administered in a fasted state, AFU GC administered in a fed state and AFU HPMC capsule administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
|
White opaque HPMC capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
White opaque HPMC capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
White opaque hard gelatin capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib GC administered in fed state
White to off white, round, biconvex coated tablet containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib ECT administered in fed state
|
EXPERIMENTAL: Sequence 6
Subjects will receive single doses of AFU HPMC capsule administered in a fed state, AFU GC administered in a fasted state, AFU ECT administered in a fasted state and AFU ECT administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
|
White opaque hard gelatin capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib GC administered in fasted state
White to off white, round, biconvex coated tablet containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib ECT administered in fasted state
White opaque HPMC capsule containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
White to off white, round, biconvex coated tablet containing afuresertib 25 mg.
Subjects will receive single oral dose of afuresertib ECT administered in fed state
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of plasma pharmacokinetics (PK) parameters of afuresertib, following administration with and without food
Time Frame: PK samples will be collected at Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours post-dose in each dosing period
|
Relative bioavailability of afuresertib after single dose of a GC, HPMC capsule and ECT, with and without high fat/calorie meal, will be determined by the following PK parameters: Area under the plasma concentration time curve- from time zero (pre-dose) to infinite time [AUC(0-inf)] and from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)], maximum observed plasma concentration (Cmax), time to Cmax (tmax), observed plasma concentration at 24 hours (C24), and minimal observed plasma concentration (Ct)
|
PK samples will be collected at Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours post-dose in each dosing period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of afuresertib as assessed by number of subjects with adverse events (AEs)
Time Frame: Up to 9 weeks
|
AEs will be collected from the start of Study Treatment and until the Follow-up contact
|
Up to 9 weeks
|
Safety and tolerability of afuresertib as assessed by clinical laboratory tests
Time Frame: Up to 9 weeks
|
Hematology, clinical chemistry and urinalysis parameters will be measured
|
Up to 9 weeks
|
Safety and tolerability of afuresertib as assessed by concomitant medications review
Time Frame: Up to 9 weeks
|
Up to 9 weeks
|
|
Safety and tolerability of afuresertib as assessed by electrocardiograms (ECG) measurements
Time Frame: Up to 9 weeks
|
Triplicate 12-lead ECGs will be collected at Screening; on Day 1 and Day 3 of each Dosing Period; and at Follow-up
|
Up to 9 weeks
|
Safety and tolerability of afuresertib as assessed by vital signs measurement
Time Frame: Up to 9 weeks
|
Vital sign measurements will include systolic and diastolic blood pressure and pulse rate
|
Up to 9 weeks
|
Change in phosphoAKT (pAKT) levels in peripheral blood samples following administration of a gelatin capsule, HPMC capsule and ECT
Time Frame: Pre-dose and 2, 12, and 24 hours post-dose in each dosing period.
|
The potential relationship between plasma PK and pharmacodynamic biomarker changes (pAKT) of each formulation will be evaluated
|
Pre-dose and 2, 12, and 24 hours post-dose in each dosing period.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 24, 2013
Primary Completion (ACTUAL)
July 12, 2013
Study Completion (ACTUAL)
July 12, 2013
Study Registration Dates
First Submitted
April 5, 2013
First Submitted That Met QC Criteria
April 5, 2013
First Posted (ESTIMATE)
April 9, 2013
Study Record Updates
Last Update Posted (ACTUAL)
November 13, 2017
Last Update Submitted That Met QC Criteria
November 8, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- 117313
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Afuresertib GC - Fasted State
-
Daewoong Pharmaceutical Co. LTD.Hanyang UniversityUnknownErosive EsophagitisKorea, Republic of
-
Konkuk University Medical CenterDaewoong Pharmaceutical Co. LTD.RecruitingErosive EsophagitisKorea, Republic of
-
Abbisko Therapeutics Co, LtdNot yet recruiting
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Universitaire Ziekenhuizen KU LeuvenCompletedObesity | Bariatric Surgery CandidateBelgium
-
Manchester Metropolitan UniversityEuropean Society for Clinical Nutrition and MetabolismRecruitingCardiovascular Diseases | Obesity | Diabetes Mellitus, Type 2United Kingdom
-
GlaxoSmithKlineCompleted
-
Vanderbilt UniversityVanderbilt University Medical CenterCompleted
-
PfizerCompletedHealthy ParticipantsBelgium